MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.
5-fluorouracil
Colorectal cancer
Drug resistance
MicroRNA
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
09
2021
accepted:
03
02
2022
pubmed:
26
2
2022
medline:
14
7
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Colorectal cancer is globally one of the most common cancers in all age groups. The current chemotherapy combinations for colorectal cancer treatment include 5-fluorouracil-based regimens; however, drug resistance remains one of the main reasons for chemotherapy failure and disease recurrence. Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression. Several microRNAs affect drug resistance by regulating the drug resistance-related target genes in colorectal cancer. These drug resistance-related miRNAs may be used as promising biomarkers for predicting drug response or as potential therapeutic targets for treating patients with colorectal cancer. This work reviews and discuss the role of selected microRNAs in 5-fluorouracil resistance and their molecular mechanisms in colorectal cancer.
Identifiants
pubmed: 35212928
doi: 10.1007/s11033-022-07227-1
pii: 10.1007/s11033-022-07227-1
doi:
Substances chimiques
MicroRNAs
0
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5165-5178Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
pubmed: 21296855
doi: 10.3322/caac.20107
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
pubmed: 15761078
doi: 10.3322/canjclin.55.2.74
Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol 14:89
pubmed: 31616522
pmcid: 6791134
Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19:3065–3071
pubmed: 22322955
doi: 10.1245/s10434-012-2246-1
Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A (2018) 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget 9:11559
pubmed: 29545919
pmcid: 5837758
doi: 10.18632/oncotarget.24338
Veenstra CM, Krauss JC (2018) Translational research in colorectal cancer: emerging systemic therapies for colorectal cancer. Clin Colon Rectal Surg 31:179
pubmed: 29720904
pmcid: 5929883
doi: 10.1055/s-0037-1602238
Patel K, Yerram SR, Azad NA, Kern SE (2012) A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing. Oncotarget 3:678
pubmed: 22824673
pmcid: 3443251
doi: 10.18632/oncotarget.554
Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH (2010) Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta Rev Cancer 1806:258–267
doi: 10.1016/j.bbcan.2010.06.001
Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N (2020) 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci 111:3142
pubmed: 32536012
pmcid: 7469786
doi: 10.1111/cas.14532
Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6–7
pubmed: 16009126
doi: 10.1016/j.cell.2005.06.036
Su Z, Yang Z, Xu Y, Chen Y, Yu Q (2015) MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 6:8474
pubmed: 25893379
pmcid: 4496162
doi: 10.18632/oncotarget.3523
Xia J, Wu Z, Yu C, He W, Zheng H, He Y, Jian W, Chen L, Zhang L, Li W (2012) miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol 227:470–480
pubmed: 22450659
doi: 10.1002/path.4030
Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12
pubmed: 16989803
doi: 10.1016/j.ydbio.2006.08.028
Yang L, Belaguli N, Berger DH (2009) MicroRNA and colorectal cancer. World J Surg 33:638–646
pubmed: 19123024
doi: 10.1007/s00268-008-9865-5
Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13:e249–e258
pubmed: 22652233
doi: 10.1016/S1470-2045(12)70073-6
Xie T, Huang M, Wang Y, Wang L, Chen C, Chu X (2016) MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer. Cell Physiol Biochem 40:62–76
pubmed: 27842308
doi: 10.1159/000452525
Zheng T, Wang J, Chen X, Liu L (2010) Role of microRNA in anticancer drug resistance. Int J Cancer Res 126:2–10
doi: 10.1002/ijc.24782
Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64–71
pubmed: 18668037
pmcid: 2745094
doi: 10.1038/nature07242
Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science 303:95–98
pubmed: 14631048
doi: 10.1126/science.1090599
Lowery AJ, Miller N, McNeill RE, Kerin MJ (2008) MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 14:360–365
pubmed: 18223209
doi: 10.1158/1078-0432.CCR-07-0992
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
pubmed: 14744438
doi: 10.1016/S0092-8674(04)00045-5
Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455:58–63
pubmed: 18668040
doi: 10.1038/nature07228
Li M, Marin-Muller C, Bharadwaj U, Chow K-H, Yao Q, Chen C (2009) MicroRNAs: control and loss of control in human physiology and disease. World J Surg 33:667–684
pubmed: 19030926
pmcid: 2933043
doi: 10.1007/s00268-008-9836-x
Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J (2009) Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer Res 125:2737–2743
doi: 10.1002/ijc.24638
Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J (2006) Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 12:2014–2024
pubmed: 16609010
doi: 10.1158/1078-0432.CCR-05-1853
Hanahan D (2012) Hallmarks of cancer: a 2012 perspective. Ann Oncol 23:ix23
doi: 10.1093/annonc/mds368
Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285:116–126
pubmed: 19464788
doi: 10.1016/j.canlet.2009.04.031
Andorfer CA, Necela BM, Thompson EA, Perez EA (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17:313–319
pubmed: 21376668
doi: 10.1016/j.molmed.2011.01.006
Garofalo M, Croce CM (2011) microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 51:25–43
pubmed: 20809797
doi: 10.1146/annurev-pharmtox-010510-100517
Aigner A (2011) MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med 89:445–457
pubmed: 21234533
doi: 10.1007/s00109-010-0716-0
Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24:3834
pubmed: 30228778
pmcid: 6141340
doi: 10.3748/wjg.v24.i34.3834
Zhou J, Zhou Y, Yin B, Hao W, Zhao L, Ju W, Bai C (2010) 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol Rep 23:121–128
pubmed: 19956872
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R (2013) Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23:186–199
pubmed: 23410973
pmcid: 3603369
doi: 10.1016/j.ccr.2012.12.020
Jiang L, Wang C, Lei F, Zhang L, Zhang X, Liu A, Wu G, Zhu J, Song L (2015) miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. Oncotarget 6:8286
pubmed: 25823655
pmcid: 4480752
doi: 10.18632/oncotarget.3221
Deng J, Lei W, Xiang X, Zhang L, Lei J, Gong Y, Song M, Wang Y, Fang Z, Yu F (2016) Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway. Oncotarget 7:10037
pubmed: 26840256
pmcid: 4891102
doi: 10.18632/oncotarget.7048
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792
pubmed: 25198391
pmcid: 4190567
doi: 10.3390/cancers6031769
Kutanzi KR, Yurchenko OV, Beland FA, Vasyl’F C, Pogribny IP (2011) MicroRNA-mediated drug resistance in breast cancer. Clin Epigenet 2:171
doi: 10.1007/s13148-011-0040-8
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz H-J, Leichman CG, Leichman L, Diasio RB (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327
pubmed: 10778957
Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR (2008) Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward? Cancer Biol Ther 7:986–994
pubmed: 18443433
doi: 10.4161/cbt.7.7.6181
Tian DH, De Silva RP, Wang T, Yan TD (2014) Open surgical repair for chronic type B aortic dissection: a systematic review. Ann Cardiothorac Surg 3:340
pubmed: 25133097
pmcid: 4128924
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A (2017) Colorectal cancer statistics, 2017. CA Cancer J Clin 67:177–193
pubmed: 28248415
doi: 10.3322/caac.21395
Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46:308–316
pubmed: 20717753
doi: 10.1007/s12033-010-9321-2
Gatti L, Zunino F (2005) Overview of tumor cell chemoresistance mechanisms. Chemosensitivity II:127–148
doi: 10.1385/1-59259-889-7:127
Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Vasyl’F C, Pogribny IP (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152–2159
pubmed: 18645025
doi: 10.1158/1535-7163.MCT-08-0021
Pan Y-Z, Gao W, Yu A-M (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112–2117
pubmed: 19581388
pmcid: 2769037
doi: 10.1124/dmd.109.027680
Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer Res 127:1785–1794
doi: 10.1002/ijc.25191
Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S, Nephew KP (2008) Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25:430–434
pubmed: 19091772
pmcid: 2642642
doi: 10.1093/bioinformatics/btn646
Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:998–1009
pubmed: 16405967
doi: 10.1016/j.febslet.2005.12.060
Hinoshita E, Uchiumi T, Taguchi K-i, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K, Kuwano M (2000) Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6:2401–2407
pubmed: 10873092
Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339–1344
pubmed: 12649196
Zunino F, Cassinelli G, Polizzi D, Perego P (1999) Molecular mechanisms of resistance to taxanes and therapeutic implications. Drug Resist Updat 2:351–357
pubmed: 11498350
doi: 10.1054/drup.1999.0108
Wang B, Lu F-Y, Shi R-H, Feng Y-D, Zhao X-D, Lu Z-P, Xiao L, Zhou G-Q, Qiu J-M, Cheng C-E (2018) MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp. Am J Cancer Res 8:2518
pubmed: 30662808
pmcid: 6325481
Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T (2015) A cancer reprogramming method using MicroRNAs as a novel therapeutic approach against colon cancer. Ann Surg Oncol 22:1394–1401
doi: 10.1245/s10434-014-4217-1
Arlanov R, Lang T, Jedlitschky G, Schaeffeler E, Ishikawa T, Schwab M, Nies A (2016) Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant. Pharmacogenomics J 16:193
pubmed: 25896536
doi: 10.1038/tpj.2015.27
Guo Y, Kotova E, Chen Z-S, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′, 3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl) adenine. J Biol Chem 278:29509–29514
pubmed: 12764137
doi: 10.1074/jbc.M304059200
To KK, Leung W, Ng SS (2015) Exploiting a novel miR-519c–HuR–ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res 338:222–231
pubmed: 26386386
doi: 10.1016/j.yexcr.2015.09.011
Shen W-W, Zeng Z, Zhu W-X, Fu G-H (2013) MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med 91:989–1000
pubmed: 23619912
doi: 10.1007/s00109-013-1037-x
Li X, Li X, Liao D, Wang X, Wu Z, Nie J, Bai M, Fu X, Mei Q, Han W (2015) Elevated microRNA-23a expression enhances the chemoresistance of colorectal cancer cells with microsatellite instability to 5-fluorouracil by directly targeting ABCF1. Curr Protein Pept Sci 16:301–309
pubmed: 25929864
doi: 10.2174/138920371604150429153309
Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29:1661–1671
pubmed: 21948564
doi: 10.1002/stem.741
Ghanbarian M, Afgar A, Yadegarazari R, Najafi R, Teimoori-Toolabi L (2018) Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p. Biomed Pharmacother 108:1070–1080
pubmed: 30372807
doi: 10.1016/j.biopha.2018.09.112
Yang G, Jiang O, Ling D, Jiang X, Yuan P, Zeng G, Zhu J, Tian J, Weng Y, Wu D (2015) MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5. Mol Med Rep 12:3930–3936
pubmed: 26043974
doi: 10.3892/mmr.2015.3890
Kim C, Hong Y, Lee H, Kang H, Lee EK (2018) MicroRNA-195 desensitizes HCT116 human colon cancer cells to 5-fluorouracil. Cancer Lett 412:264–271
pubmed: 29080751
doi: 10.1016/j.canlet.2017.10.022
Fang L, Li H, Wang L, Hu J, Jin T, Wang J, Yang BB (2014) MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 5:2974
pubmed: 24912422
pmcid: 4102784
doi: 10.18632/oncotarget.1614
Zhang J, Roberts TM, Shivdasani RA (2011) Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141:50–61
pubmed: 21723986
doi: 10.1053/j.gastro.2011.05.010
Yin J, Shen X, Li M, Ni F, Xu L, Lu H (2018) miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1. Oncol Lett 16:3587–3592
pubmed: 30127965
pmcid: 6096256
Heydari K, Saidijam M, Reza Sharifi M, Asl SS, Shabab N, Najafi R (2018) The effect of miR-200c inhibition on chemosensitivity (5-FluoroUracil) in colorectal cancer. Pathol Oncol Res 24:145–151
pubmed: 28411308
doi: 10.1007/s12253-017-0222-6
Zhang Y, Geng L, Talmon G, Wang J (2015) MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 290:6215–6225
pubmed: 25616665
pmcid: 4358260
doi: 10.1074/jbc.M114.620252
Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, Lauffenburger DA, Sarkaria JN, Samson LD (2017) DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer Res 77:198–206
pubmed: 27793847
doi: 10.1158/0008-5472.CAN-16-1151
Sadik H, Korangath P, Nguyen NK, Gyorffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Munoz TG (2016) HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells. Cancer Res 76:4443–4456
pubmed: 27302171
pmcid: 4970943
doi: 10.1158/0008-5472.CAN-16-0774
Reardon JT, Vaisman A, Chaney SG, Sancar A (1999) Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV)(JM216) platinumintrastrand DNA diadducts. Cancer Res 59:3968–3971
pubmed: 10463593
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L (2014) miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol 8:83–92
pubmed: 24145123
doi: 10.1016/j.molonc.2013.09.004
Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci 107:21098–21103
pubmed: 21078976
pmcid: 3000294
doi: 10.1073/pnas.1015541107
Liu R-L, Dong Y, Deng Y-Z, Wang W-J, Li W-D (2015) Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumor Biol 36:5011–5019
doi: 10.1007/s13277-015-3152-5
Ye L, Jiang T, Shao H, Zhong L, Wang Z, Liu Y, Tang H, Qin B, Zhang X, Fan J (2017) miR-1290 is a biomarker in DNA-mismatch-repair-deficient colon cancer and promotes resistance to 5-fluorouracil by directly targeting hMSH2. Mol Ther Nucleic Acids 7:453–464
pubmed: 28624221
pmcid: 5443909
doi: 10.1016/j.omtn.2017.05.006
Longley D, Johnston P (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292
pubmed: 15641020
doi: 10.1002/path.1706
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Chai H, Liu M, Tian R, Li X, Tang H (2011) miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin 43:217–225
pubmed: 21242194
doi: 10.1093/abbs/gmq125
Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J, Wang T (2016) Micro RNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10. J Cell Mol Med 20:360–369
pubmed: 26647742
doi: 10.1111/jcmm.12742
Meng X, Fu R (2018) miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther 11:1757
pubmed: 29636622
pmcid: 5881530
doi: 10.2147/OTT.S159093
Tong Z, Liu N, Lin L, Guo X, Yang D, Zhang Q (2015) miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. Biomed Pharmacother 75:129–136
pubmed: 26297542
doi: 10.1016/j.biopha.2015.07.036
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, Lai M (2011) MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Dis 18:1702–1710
doi: 10.1038/cdd.2011.28
Borralho PM, Kren BT, Castro RE, Moreira da Silva IB, Steer CJ, Rodrigues CM (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276:6689–6700
pubmed: 19843160
doi: 10.1111/j.1742-4658.2009.07383.x
Zhang Y, Talmon G, Wang J (2015) MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Cell Death Discov 6:e1845
doi: 10.1038/cddis.2015.200
Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J (2013) miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 73:6435–6447
pubmed: 23950211
doi: 10.1158/0008-5472.CAN-12-3308
Xu K, Chen G, Qiu Y, Yuan Z, Li H, Yuan X, Sun J, Xu J, Liang X, Yin P (2017) miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget 8:21719
pubmed: 28423513
pmcid: 5400618
doi: 10.18632/oncotarget.15559
Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J (2013) miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 52:70–78
pubmed: 22121083
doi: 10.1002/mc.21832
Karaayvaz M, Zhai H, Ju J (2013) miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Discov 4:e659–e659
doi: 10.1038/cddis.2013.193
Li P-L, Zhang X, Wang L-L, Du L-T, Yang Y-M, Li J, Wang C-X (2015) MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis 36:1484–1493
pubmed: 26442524
Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS-B, Leong C-O (2012) Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Lett 314:166–175
pubmed: 22033244
doi: 10.1016/j.canlet.2011.09.025
Liang T, Zhang X, Xue W, Zhao S, Zhang X, Pei J (2014) Curcumin induced human gastric cancer BGC-823 cells apoptosis by ROS-mediated ASK1-MKK4-JNK stress signaling pathway. Int J Mol Sci 15:15754–15765
pubmed: 25198898
pmcid: 4200840
doi: 10.3390/ijms150915754
Stander XX, Stander BA, Joubert AM (2015) Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways. Cell Physiol Biochem 35:1499–1526
pubmed: 25791820
doi: 10.1159/000369710
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W, Jiang X, Zhang C, Qu J (2015) MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol 230:535–545
pubmed: 23526568
doi: 10.1002/jcp.24366
Han J, Liu Z, Wang N, Pan W (2016) MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein. Oncol Rep 36:542–550
pubmed: 27221209
doi: 10.3892/or.2016.4810
Mizushima N, Komatsu M (2011) Autophagy renovation of cells and tissues. Cell 147:728–741
pubmed: 22078875
doi: 10.1016/j.cell.2011.10.026
Zhang H, Tang J, Li C, Kong J, Wang J, Wu Y, Xu E, Lai M (2015) MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 356:781–790
pubmed: 25449431
doi: 10.1016/j.canlet.2014.10.029
Yu X, Shi W, Zhang Y, Wang X, Sun S, Song Z, Liu M, Zeng Q, Cui S, Qu X (2017) CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer. Sci Rep 7:42226
pubmed: 28176874
pmcid: 5296742
doi: 10.1038/srep42226
Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X, Zhang X (2016) miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol Med 37:1030–1038
pubmed: 26935807
doi: 10.3892/ijmm.2016.2492
Chai J, Dong W, Xie C, Wang L, Han DL, Wang S, Guo HL, Zhang ZL (2015) MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life 67:191–201
pubmed: 25873402
doi: 10.1002/iub.1361
Amstutz U, Froehlich TK, Largiadèr CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321–1336
pubmed: 21919607
doi: 10.2217/pgs.11.72
Deng J, Lei W, Fu J-C, Zhang L, Li J-H, Xiong J-P (2014) Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 443:789–795
pubmed: 24275137
doi: 10.1016/j.bbrc.2013.11.064
Xu F, Ye ML, Zhang YP, Li WJ, Li MT, Wang HZ, Qiu X, Xu Y, Yin JW, Hu Q (2020) MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Cancer Sci 111:1528
pubmed: 32073706
pmcid: 7226198
doi: 10.1111/cas.14356
Sun Z, Zhou N, Han Q, Zhao L, Bai C, Chen Y, Zhou J, Zhao R (2015) MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. Clin Transl Oncol 17:876–883
pubmed: 26055341
doi: 10.1007/s12094-015-1318-7
Li T, Gao F, Zhang X-P (2015) miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncol Rep 33:607–614
pubmed: 25482885
doi: 10.3892/or.2014.3646
Morris J (2001) Genes, genetics, and epigenetics: a correspondence. Science 293:1103–1105
pubmed: 11498582
doi: 10.1126/science.293.5532.1103
Berman M, Mattheolabakis G, Suresh M, Amiji M (2016) Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opin Drug Deliv 13:987–998
pubmed: 27097309
doi: 10.1080/17425247.2016.1178236
Li E, Beard C, Jaenisch R (1993) Role for DNA methylation in genomic imprinting. Nature 366:362
pubmed: 8247133
doi: 10.1038/366362a0
Pogribny IP, Beland FA (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 66:2249–2261
pubmed: 19326048
doi: 10.1007/s00018-009-0015-5
Duursma AM, Kedde M, Schrier M, Le Sage C, Agami R (2008) miR-148 targets human DNMT3b protein coding region. RNA Biol 14:872–877
doi: 10.1261/rna.972008
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805–15810
pubmed: 17890317
pmcid: 2000384
doi: 10.1073/pnas.0707628104
Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295
pubmed: 19308066
doi: 10.1038/nrg2540
Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Gitt A (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67:1424–1429
pubmed: 17308079
doi: 10.1158/0008-5472.CAN-06-4218
Shi L, Li X, Wu Z, Li X, Nie J, Guo M, Mei Q, Han W (2018) DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. J Genet Genomics 45:205–214
pubmed: 29735329
doi: 10.1016/j.jgg.2018.04.003
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193
pubmed: 10490031
doi: 10.1038/43710
Yang X-J, Grégoire S (2005) Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 25:2873–2884
pubmed: 15798178
pmcid: 1069616
doi: 10.1128/MCB.25.8.2873-2884.2005
Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M (2009) Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28:4065–4074
pubmed: 19734943
pmcid: 2783211
doi: 10.1038/onc.2009.274
Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, Wang Z, Liu J, Cai G (2016) miR-139-5p inhibits the epithelial-mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by downregulating BCL2. Sci Rep 6:27157
pubmed: 27244080
pmcid: 4886683
doi: 10.1038/srep27157
Ren L-L, Yan T-T, Shen C-Q, Tang J-Y, Kong X, Wang Y-C, Chen J, Liu Q, He J, Zhong M (2018) The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. Cell Death Discov 9:1–14
doi: 10.1038/s41419-017-0012-9
Ding J, Zhao Z, Song J, Luo B, Huang L (2018) MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial–mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin 50:597–604
pubmed: 29701752
doi: 10.1093/abbs/gmy040
Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Int J Biol Chem 283:14910–14914
doi: 10.1074/jbc.C800074200
Tanaka S, Hosokawa M, Yonezawa T, Hayashi W, Ueda K, Iwakawa S (2014) Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. Biol Pharm Bull b14-00695
Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M (2013) Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci 14:21087–21113
pubmed: 24152442
pmcid: 3821660
doi: 10.3390/ijms141021087
Afify SM, Seno M (2019) Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers 11:345
pmcid: 6468812
doi: 10.3390/cancers11030345
Kozovska Z, Gabrisova V, Kucerova L (2014) Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother 68:911–916
pubmed: 25458789
doi: 10.1016/j.biopha.2014.10.019
Takahashi R-u, Miyazaki H, Ochiya T (2014) The role of microRNAs in the regulation of cancer stem cells. Front Genet 4:295
pubmed: 24427168
pmcid: 3879439
doi: 10.3389/fgene.2013.00295
Becker KA, Ghule PN, Therrien JA, Lian JB, Stein JL, Van Wijnen AJ, Stein GS (2006) Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J Cell Physiol 209:883–893
pubmed: 16972248
doi: 10.1002/jcp.20776
Ye J, Wang Z, Zhao J, Chen W, Wu D, Wu P, Huang J (2017) MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer. Mol Med Rep 15:1037–1042
pubmed: 28112364
pmcid: 5367372
doi: 10.3892/mmr.2017.6135
Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y, Liang Y, Cao L, Li X, Li R (2017) Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget 8:49807
pubmed: 28591704
pmcid: 5564809
doi: 10.18632/oncotarget.17971
Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 15:3325–3332
pubmed: 19417016
pmcid: 3700356
doi: 10.1158/1078-0432.CCR-08-3010
Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT (2009) Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA 106:10746–10751
pubmed: 19520829
pmcid: 2705554
doi: 10.1073/pnas.0811817106
Brownlie RJ, Zamoyska R (2013) T cell receptor signalling networks: branched, diversified and bounded. Nat Rev Immunol 13:257–269
pubmed: 23524462
doi: 10.1038/nri3403
Skafi N, Fayyad-Kazan M, Badran B (2020) Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression. Gene 754:144888
pubmed: 32544493
doi: 10.1016/j.gene.2020.144888
Belkaid Y, Tarbell K (2009) Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 27:551–589
pubmed: 19302048
doi: 10.1146/annurev.immunol.021908.132723
Liston A, Lu L-F, O’Carroll D, Tarakhovsky A, Rudensky AY (2008) Dicer-dependent microRNA pathway safeguards regulatory T cell function. Exp Med 205:1993–2004
doi: 10.1084/jem.20081062
Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA (2008) Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. Exp Med 205:1983–1991
doi: 10.1084/jem.20080707
Khorrami S, Zavaran Hosseini A, Mowla SJ, Soleimani M, Rakhshani N, Malekzadeh R (2017) MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumor Biol 39:1010428317698365
doi: 10.1177/1010428317698365
Pouya FD, Rasmi Y, Gazouli M, Zografos E, Nemati M (2021) MicroRNAs as therapeutic targets in breast cancer metastasis. Drug Deliv Transl Res. https://doi.org/10.1007/s13346-021-00999-2
doi: 10.1007/s13346-021-00999-2
pubmed: 33987801